May 20, 2024
(press release)
–
AstraZeneca has been ordered to pay $107.5 million to Pfizer in damages for infringing Pfizer's patents, GlobalData reported May 20. A jury found that Tagrisso, an AstraZeneca lung cancer drug, violated Pfizer's Wyeth unit's patent rights under two patents. Pfizer claimed Tagrisso's use of kinase inhibitors for cancer treatment infringed on its patent for Nerlynx, a breast cancer drug. AstraZeneca refuted the allegations and challenged the validity of the patents. The U.S. District Court in Delaware ruled in favor of Pfizer; however, the case is set to continue in a separate bench trial in June to address AstraZeneca's remaining defenses.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
